HEALTH Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer Monday, April 13, 2026 · transgene s.a. Advertisement Read Original Article → Related Dispatches [US] · Jul 30 FTC, Hims and Hers, Ebola vaccine: Morning Rounds [CA] · Jul 30 Leaked health care report shows Lloydminster services 'struggling to keep up': Sask. NDP [US] · Jul 30 STAT+: Tracking the FDA expert review of Replimune’s melanoma treatment